AKTS 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• advance [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors and [225Ac]Ac-AKY-2519 for B7-H3 expressing tumors through clinical trials;

• continue investigational new drug, or IND, -enabling preclinical studies for our other programs;

• If our development efforts for our current or future product candidates are successful and result in regulatory approval or if we enter into additional license or collaboration agreements with third parties, we may generate revenue in the future from product sales, payments from such license or coll…

• complete clinical trials, our ability to generate future revenues, and our results of operations and financial position would be adversely affected.

• $3.6 million increase related to the operations of our ongoing Phase 1b clinical trial for [225Ac]Ac-AKY-1189;

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• advance our lead product candidate, [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors, through clinical trials;

• commence clinical trials for [225Ac]Ac-AKY-2519 for B7-H3 expressing tumors;

• continue IND-enabling preclinical studies for our other programs;

• If our development efforts for our current or future product candidates are successful and result in regulatory approval or if we enter into additional license or collaboration agreements with third parties, we may generate revenue in the future from product sales, payments

• from such license or collaboration agreements, or any combination thereof. We cannot predict if, when or to what extent we will generate revenue as we may never succeed in obtaining regulatory approval for any of our product candidates. If we fail to complete preclinical and clinical development of …

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

• (1) This amount represents the maximum total shares that could be sold under the plan.

• (2) On July 7, 2026, Ms. Ron-Bigger terminated her trading plan prior to any shares of common stock being sold pursuant to the trading plan.